Stockscreener 앱 받기
4.74
3.85%
-0.19
시간 외 거래:
4.92
0.18
+3.80%
Cingulate Inc 주식(CING)의 최신 뉴스
Why Is CING Stock Jumping Over 4% In Overnight Trading? - Stocktwits
CING Q1 2026 Earnings: Wider-than-expected loss as pre-revenue biotech continues pipeline development - newsline.com
Insider Makes Bold Move With Major Cingulate Inc. Stock Purchase - TipRanks
CING Maintained by Ascendiant Capital -- Price Target Lowered to $52 - GuruFocus
Cingulate director Hargroves buys $490,271 of common stock By Investing.com - Investing.com Australia
Cingulate director Hargroves buys $490,271 of common stock - Investing.com
Cingulate (CING) director-linked LLC buys shares, warrants as options granted - Stock Titan
Cingulate (CING) director reports initial share and warrant holdings - Stock Titan
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (NASDAQ: CING) Following FDA Complete Response Letter - citybuzz -
FDA focuses on manufacturing for Cingulate CTx-1301, not safety - Stock Titan
FDA slaps CRL on Cingulate’s CTx-1301 NDA - The Pharma Letter
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 - TMX Newsfile
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301 - AJMC
FDA Issues Complete Response Letter for Cingulate ADHD Drug CTx-1301 - Patient Care Online
Biopharma bites: FDA rebuffs Cingulate's ADHD hopeful, plus Contraline's male contraceptive funding - FirstWord Pharma
FDA rejects Cingulate's application for ADHD medicine - The Business Journals
FDA Sends Complete Response Letter for Cingulate's CTx-1301 | PharmExec - PharmExec.com
FDA Issues CRL for CTx-1301 in ADHD Over CMC Concerns - HCPLive
Cingulate Gets FDA Request for Updates on ADHD Drug Application - Moomoo
Cingulate Inc - Reuters
Cingulate Inc. Q1 2026 Earnings: Wider-than-Expected Loss, Yet Shares Rally 19%Earnings Preview - thelegaladvocate.com
Cingulate Receives FDA Complete Response Letter for CTx-1301 ADHD Drug; No Clinical Safety or Efficacy Concerns Identified 1 - Minichart
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues - Reuters
FDA Sends CRL to Cingulate for CTx-1301 - PharmExec.com
ADHD drug delivery specialist Cingulate hit with manufacturing-related FDA rejection - Fierce Pharma
Cingulate stock tumbles after FDA issues response letter - Investing.com
Cingulate receives FDA complete response letter for ADHD drug By Investing.com - Investing.com South Africa
Cingulate stock tumbles after FDA issues response letter By Investing.com - Investing.com Australia
Cingulate receives FDA complete response letter for ADHD drug - Investing.com
Cingulate Faces FDA Delay But Maintains ADHD Drug Plans - TipRanks
Cingulate Receives Complete Response Letter from FDA for CTx-1301 - The Manila Times
Cingulate receives FDA complete response letter for CTx-1301; CMC requests, ~$30M cash - TradingView
FDA sends CRL on Cingulate (NASDAQ: CING) ADHD drug CTx-1301 - Stock Titan
US FDA declines to approve Cingulate's ADHD drug - Yahoo Finance
Reportable, Inc. - TMX Newsfile
Cingulate’s ADHD Drug Is Near An FDA Verdict - Finimize
Cingulate Nears FDA Verdict on ADHD Drug Amid Manufacturing Hurdles - BriefGlance
Executive pay and equity plan on agenda at Cingulate (NASDAQ: CING) - Stock Titan
Cingulate Awaits FDA Decision On ADHD Therapy CTx-1301 - RTTNews
CING Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Continues R&D InvestmentEarnings Cycle Outlook - The League of Women Voters of Texas
CING Q1 2026 Earnings: Wider-than-Expected Loss Sends Shares LowerRevenue Growth Outlook - thelegaladvocate.com
Cingulate Inc. (CING) Plunges 17% as Selling Pressure IntensifiesEase of Movement - thelegaladvocate.com
Analysts Are Bullish on These Healthcare Stocks: Roche Holding AG (RHHVF), Cingulate Inc (CING) - The Globe and Mail
H.C. Wainwright Maintains Cingulate(CING.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Cingulate Inc. (CING) Surges 8.4% as Bullish Momentum BuildsImpulse Wave - thelegaladvocate.com
CING Reiterated by HC Wainwright & Co. -- Price Target Maintained at $20 - GuruFocus
Cingulate stock reaffirmed at Buy by H.C. Wainwright ahead of FDA decision - Investing.com UK
1.27%
1.43%
자본화:
|
볼륨(24시간):